Friday, July 31, 2026

Paul Atkins Declares End of SEC’s Hostile Crypto Approach, Promises Clearer Rules

SEC Chair Gary Gensler announces a shift in regulatory approach for the digital asset industry, aiming to provide clear rules instead of restrictions.

Jordan’s Tactical Win Over North Korea: A Sneak Peek into Their World Cup Qualifier Strategy

Jordan defeated North Korea 2-1 in a private friendly match, preparing for World Cup qualifiers. They previously drew 0-0.

PREPARING FOR THE FIRST STRIKE : South Korea’s Elite Units And AI Drones Ready To Decapitate The Enemy

South Korean defense firms are thriving amid Middle East tensions, boosting exports and fostering growth for startups and suppliers.

Tag: SK Bioscience

SK Bioscience Achieves WHO PQ Certification: What This Means for Global Vaccine Supply

SK Bioscience completed WHO's triennial review for its vaccines, enhancing international trust in its quality and operational systems.

WHO Warns of Next Pandemic as Infectious Disease Preparedness Remains Critical; SK Bioscience Draws Attention

SK Bioscience enhances South Korea's pandemic preparedness with vaccine innovations and global partnerships, focusing on future growth.

SK Bioscience Licenses CDC Rotavirus Vaccine Candidate, Expands Global Vaccine Pipeline

SK Bioscience partners with the CDC to develop a rotavirus vaccine, aiming to enhance global health and expand its vaccine portfolio.

SK Bioscience Opens Songdo Headquarters to Families as It Expands Employee-Centered Corporate Culture

SK Bioscience hosted a family open house at its new headquarters, showcasing its vision and engaging activities for employees' families.

SK Bioscience Builds Latin American Growth Momentum With Local Vaccine Manufacturing Collaboration in Colombia

SK bioscience accelerates its expansion into the Latin American market with its self-developed vaccine.

SK Bioscience Pours 4 Billion KRW into RSM01, Accelerating RSV Antibody Trials

SK Bioscience secures funding from the Light Foundation to support clinical trials for its RSV prevention monoclonal antibody RSM01.

Why Ebola Now? SK Bioscience Joins a $30 Million Global Push to Rethink Ebola Vaccine Production

SK Bioscience secures funding to enhance Ebola vaccine production, improving yield and stability for better accessibility amid outbreaks.

How SK Bioscience Plans to Dominate the Global Vaccine Market in 2026

SK Bioscience enhances its operational system with new COO and key appointments to boost global competitiveness and vaccine development.

Top News

- Our Sponsors Ad -

Follow us